Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 75.00
Bid: 73.00
Ask: 77.00
Change: 7.50 (11.11%)
Spread: 4.00 (5.479%)
Open: 67.50
High: 78.50
Low: 67.50
Prev. Close: 67.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 May 2024 07:00

RNS Number : 3714P
Feedback PLC
22 May 2024
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

Feedback plc

 

Trading Update

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces a trading update for the financial year ended 31 May 2024 ("FY2024") (the "Period").

 

FY2024 revenue is expected to be around £1.2m, approximately 15% higher than the prior year. The EBITDA loss for FY2024 is expected to improve in comparison to market expectations, despite the slower than anticipated revenue growth in FY2024, as the Company continues to optimise its cost base. As such, the Company's FY2024 closing cash position is expected to be at least in line with market expectations. The Company's cash balance as at 30 April 2024 was £4.3m.

 

NHS procurement processes are more protracted for novel technologies such as Bleepa compared to the replacement of existing similar services where NHS procurement and funding is relatively more straightforward. The Company has been nurturing a number of commercial opportunities with national and regional NHS organisations which we had hoped to convert during the Period; unfortunately, the financial and operational pressures facing the NHS have delayed a number of these strategic conversations and consequently, the Board now believes that these larger NHS opportunities are likely to mature during the upcoming financial year.

 

 

Dr Tom Oakley, CEO commented:

 

"Despite a delay in some of our larger national and regional NHS opportunities we have delivered revenue growth in FY2024 and optimised our cost base.

 

"Based on information currently available to us we anticipate that new funding streams will land in the system that will enable us to progress with our wider pipeline of opportunity and build on the fantastic foundation that we have built to date, and we are therefore expecting these opportunities to convert to contract and be recognised within FY2025 revenue.

 

"In the meantime, this has given us an opportunity to continue pursuing our international opportunities and we are making promising progress in India around TB screening and other upcoming opportunities that have been unlocked by our in-country MD, Rohit Singh, having established the right to sell Bleepa as a medical device."

 

 

--Ends--

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Joe Walker

07748 325 236 or 07407 020 470

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment, with greater connectivity across organisations.

 

Our products Bleepa® and CareLocker® work together to deliver unparalleled value to our customers. Bleepa® is our application layer and sits on top of CareLocker® as our data layer. Bleepa® is a clinician facing platform that displays clinical results from a patient's CareLocker® at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker® data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFZGZKLMKGDZM
Date   Source Headline
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India
21st Mar 20247:00 amRNSFurther CDC Pilot Programme Secured
23rd Feb 202411:03 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSHalf-year Report
21st Feb 20247:00 amRNSMedical Imaging Partnership Pilot Agreement
6th Feb 20247:00 amRNSNotice of Results & Investor Presentation
19th Dec 20237:01 amRNSHalf Year Trading Update
19th Dec 20237:00 amRNSAward of Pilot Funding
26th Oct 20232:24 pmRNSResult of AGM
25th Oct 20235:53 pmRNSDirector Dealing
27th Sep 202312:15 pmRNSNotice of AGM
12th Sep 20237:00 amRNSFinal Results
5th Sep 20237:00 amRNSNotice of Results & Investor Presentation
19th Jun 20237:00 amRNSYear End Trading Update
4th Apr 20237:00 amRNSBleepa-CareLocker contract extension with QVH
7th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:56 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSNotice of Results, Analyst & Investor Presentation
22nd Dec 202212:08 pmRNSDirector/PDMR Shareholding: Correction
22nd Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20227:00 amRNSHalf Year Trading Update
1st Nov 20223:36 pmRNSTotal Voting Rights
13th Oct 20222:55 pmRNSResult of AGM & Proposed Share Consolidation
29th Sep 20223:46 pmRNSHolding(s) in Company
20th Sep 20223:26 pmRNSNotice of AGM & Proposed Share Consolidation
20th Sep 20227:00 amRNSFinal Results
13th Sep 20227:00 amRNSNotice of Results & Investor Presentation
6th Sep 20227:00 amRNS12 month contract for Sussex CDC pilot extension
19th Jul 20227:00 amRNSContract Update
16th Jun 20227:00 amRNSYear End Trading Update
1st Jun 20227:00 amRNSTrading Update & Director Appointment
12th May 202212:44 pmRNSChange of Registered Office
12th Apr 20227:00 amRNSBleepa wins two NHS Contract Awards
31st Mar 20227:00 amRNSBleepa TB Screening Pilot Now Live in Odisha
23rd Feb 20227:00 amRNSGrant of Options and PDMR dealing
10th Feb 20227:00 amRNSInterim Results
31st Jan 20227:00 amRNSNotice of Results
13th Dec 20217:00 amRNSPartnership with Amazon Web Services
6th Dec 20213:06 pmRNSHolding(s) in Company
2nd Dec 202110:20 amRNSDirector/PDMR Shareholding
2nd Dec 20219:54 amRNSHolding(s) in Company
1st Dec 20214:27 pmRNSHolding(s) in Company
1st Dec 20213:09 pmRNSHolding(s) in Company
30th Nov 20214:05 pmRNSHolding(s) in Company
29th Nov 20211:36 pmRNSDirector Appointment
29th Nov 20211:35 pmRNSResults of AGM, Open Offer, Issue of Equity & TVR
18th Nov 202112:15 pmRNSHolding(s) in Company
16th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20211:52 pmRNSResult of Placing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.